Precision cancer diagnostics specialist Epredia, a subsidiary of PHC Holdings Corporation (TSE:6523), and Mindpeak, a provider of AI solutions for clinical and research pathology, on Tuesday announced a distribution agreement to supply Mindpeak's AI-based image recognition modules to Epredia's digital pathology customers in the European Union.

The software provides pixel-level analysis of digital tissue images to support objective, reproducible assessments across breast, lung, and gastrointestinal cancers, biomarker quantification, and research applications, while operating without cloud connectivity to maintain data privacy. Mindpeak's portfolio includes both CE-marked and research-use-only modules.

Epredia will offer the AI tools for clinical diagnostics, translational research, and pharmaceutical development and plans to explore integration into its E1000 Dx Digital Pathology Solution workflow to enable streamlined data exchange and high-throughput image review of up to 1,500 slides daily.

This agreement expands Epredia's end-to-end pathology portfolio spanning consumables, instruments, and advanced image management systems with AI-enabled capabilities.